Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes

Diabetes and Vascular Disease Research

Volumn 12, Issue 5, 2015, Pages 352-358

  Sjöström, C David ^a   Johansson, Peter ^a   Ptaszynska, Agata ^b   List, James ^b   Johnsson, Eva ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

blood pressure; Dapagliflozin; hypertension; sodium glucose co transporter 2 inhibitor; type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; PLACEBO; THIAZIDE DIURETIC AGENT; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; BLOOD PRESSURE MEASUREMENT; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84938687573     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115585298     Document Type: Article

References (23)

1. Sowers JR, Epstein M, Frohlich ED,. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-1059.
2. Davis TM, Millns H, Stratton IM,. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999; 159: 1097-1103.
3. Hu G, Sarti C, Jousilahti P,. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 2005; 36: 2538-2543.
4. Obesity and Overweight. World Health Organization: global strategy on diet, physical activity and health., 2003, http://www.who.int/dietphysicalactivity/media/en/gsfs-obesity.pdf
5. Borne AT, Truett AA, Monteiro MP,. Changes in skeletal muscle vascular resistance with weight gain: associations with insulin and sympathetic activity. Obes Res 1999; 7: 68-75.
6. Hsueh WA, Wyne K., Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 2011; 13: 224-237.
7. Manrique C, Lastra G, Gardner M,. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 2009; 93: 569-582.
8. Brands MW, Manhiani MM., Sodium-retaining effect of insulin in diabetes. Am J Physiol Regul Integr Comp Physiol 2012; 303: R1101-R1109.
9. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.
10. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
11. Mancia G, Fagard R, Narkiewicz K,. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
12. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl. 1): S14-S80.
13. Paneni F., 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps. Diab Vasc Dis Res 2014; 11: 5-10.
14. Law MR, Morris JK, Wald NJ., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
15. List JF, Woo V, Morales E,. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
16. Bailey CJ, Gross JL, Hennicken D,. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: 43.
17. Ferrannini E, Ramos SJ, Salsali A,. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
18. Nauck MA, Del Prato S, Duran-Garcia S,. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 2014; 16: 1111-1120.
19. Strojek K, Yoon KH, Hruba V,. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014; 5: 267-283.
20. Lambers Heerspink HJ, de Zeeuw D, Wie L,. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-862.
21. Sjostrom CD, Hashemi M, Sugg J,. Dapagliflozin-induced weight loss impacts 24 week HbA1c and blood pressure levels. Diabetolgia 2013; 56: S81.
22. Dornfeld LP, Maxwell MH, Waks AU,. Obesity and hypertension: long-term effects of weight reduction on blood pressure. Int J Obes 1985; 9: 381-389.
23. Sjostrom CD, Peltonen M, Sjostrom L., Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res 2001; 9: 188-195.